XWRAP Shows Early Promise in Chronic Wound Trial
Interim trial data indicates a higher rate of wound closure compared to standard care over a 12-week primary endpoint.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Do you trust new clinical treatment results to accurately reflect real-world benefits?
Applied Biologics has released interim results from its CAMPX clinical trial evaluating XWRAP as a treatment for chronic wounds. The research, which is still in the trial phase, measured outcomes for 129 patients across 19 sites.
Why it matters
The study provides early evidence on whether XWRAP, when added to standard wound care, improves closure rates compared to traditional protocols alone. These findings help define the potential efficacy of the treatment before final results are available.
In the intention-to-treat analysis, XWRAP achieved a 17.9% complete wound closure rate compared to 11.3% for the control group. Patients receiving the treatment also showed a 31.6% median percent area reduction against 20.0% in the control arm.
The players
Applied Biologics
A biotech firm focused on developing therapeutic solutions for chronic wound management.
The details
The CAMPX trial assesses XWRAP in combination with standard care, a baseline treatment protocol that typically includes cleansing and moisture-balancing dressings. Researchers determined complete wound closure by reviewing de-identified images of the affected areas. Two blinded specialists—experts who assess medical results without knowing which treatment the patient received—independently graded the images, with a third medical lead resolving any disagreements.
Timeline
December 2025: Data lock for interim analysis.
October 28, 2026: Publication of interim trial results.
The Tech Race
This report marks a mid-point update on the ongoing CAMPX clinical trial. It offers an early view of how this therapeutic candidate performs against established standard-of-care benchmarks in chronic wound healing.
XWRAP remains an experimental treatment, and patients cannot yet access it outside of the ongoing clinical trial. The company has not provided a timeline for commercial availability or regulatory submission.
The takeaway
The study offers a benchmark for XWRAP performance but stops short of proving clinical superiority. Readers should track the final database lock to see if these interim gains in wound closure hold across the full cohort.
Further reading
For broader trends in medical innovation, visit the Biotech section.
More information
View the peer-reviewed trial manuscript for detailed methodology and results.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust new clinical treatment results to accurately reflect real-world benefits?
